After the FDA rejected its proposed MDMA treatment, Lykos Therapeutics is laying off 75 percent of its staff and its founder has left the company. Wired Read More
After the FDA rejected its proposed MDMA treatment, Lykos Therapeutics is laying off 75 percent of its staff and its founder has left the company.
